Apomorphine Veterinary Grade API for Tablets / Injections / Capsules / Powders / Granules / Premix / Solutions is supplied as apomorphine hydrochloride hemihydrate, CAS 41372-20-7, the chloride salt of (6aR)-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline-10,11-diol. The chemical model is the hemihydrate crystalline form rather than the free base, because the free base oxidizes rapidly and exhibits poor aqueous solubility. The salt is a white to faintly grey crystalline powder with aqueous solubility above 20 mg/mL at 20–25 °C. Non-sterile veterinary grade is used for tablets, capsules, powders, granules, and premixes; injectable solutions and some oral solutions require a sterile, non-pyrogenic bulk powder with bacterial endotoxins ≤0.5 EU/mg and particulate matter controlled to USP <788> for small-volume injectables. The primary veterinary use is induction of emesis in dogs by D2 receptor agonism in the chemoreceptor trigger zone. Published canine dose ranges are 0.02–0.04 mg/kg intravenously and 0.03–0.06 mg/kg subcutaneously or intramuscularly, with onset usually within 2–5 minutes after IV administration and 5–10 minutes after SC/IM administration. The API is supplied as dry powder rather than as a prefilled 10 mg/mL human injection concentrate, so the formulator controls antioxidant type, osmolality, and final sterilization independently.

How Do Oxygen, Trace Metals, and Light Limit the Processing Window for Aqueous Apomorphine?

Apomorphine hydrochloride contains a 10,11-catechol moiety that undergoes oxidation to ortho-quinone derivatives and polymerized melanin-like chromophores; the visible green-to-brown color change is the most sensitive release and stability indicator. In aqueous solution, degradation is accelerated above pH 4.0, by dissolved oxygen above 1.0 mg/L, by Fe²⁺ or Cu²⁺ above 0.1 mg/L, and by direct sunlight. Aseptic solution manufacture therefore operates within a pH 2.5–4.0 window, with headspace oxygen below 2.0% v/v and light-resistant Type I borosilicate glass vials per USP <660>. Disodium edetate at 0.05% w/v is included when metal-catalyzed oxidation cannot be excluded by vessel passivation and filtered water source controls. Sodium metabisulfite at 0.1–1.0 mg/mL is the common antioxidant, but sulfite-sensitive target species may require ascorbic acid at 0.05% w/v; the choice is justified by forced degradation studies under ICH Q1A. Published kinetic data for apomorphine hydrochloride specifically in diluted veterinary premix are limited, so the degradation rate constant at the final fill concentration should be measured rather than extrapolated from human drug product stability data.

For low-dose tablet and capsule manufacture, the API is pre-dispersed by geometric dilution into an intragranular blend of lactose monohydrate and microcrystalline cellulose; unit strengths of 1 mg, 2 mg, 4 mg, and 6 mg per core produce drug loads below 0.5% w/w. Direct compression in a bin blender at 10–25 rpm continues until blend uniformity meets USP <905> with an internal acceptance value of RSD ≤5.0%. Cores are compressed to hardness of 3–7 kp, with disintegration time ≤15 minutes in 0.1 M hydrochloric acid at 37 °C per USP <701>. Dry granulation by roller compaction is preferred over aqueous wet granulation because residual moisture above 3.0% w/w accelerates surface oxidation and produces grey-green specking. If wet granulation is unavoidable, an ethanolic polyvinylpyrrolidone binder at 5% w/w is used with product temperature below 35 °C and vacuum drying at 50–60 °C to moisture below 3.0%. Capsule filling with size 3 or size 4 hard gelatin capsules uses dosator or tamping-pin equipment; 0.5% w/w colloidal silicon dioxide and 1.0% w/w sodium stearyl fumarate are added to improve powder flow. A recurring production failure on dosator lines is drug-rich particle adhesion to stainless steel compression fingers when electrostatic charge accumulates; grounding the machine and maintaining relative humidity below 40% reduces this effect. For powders and low-dose capsule blends, the API is first prepared as a 1:10 w/w trituration with lactose monohydrate, then diluted to a 1:100 w/w premix before final dilution to minimize segregation.

When Aseptic Filtration Replaces Terminal Sterilization in Apomorphine Injection Lines

Steam terminal sterilization at 121 °C for 15 minutes is generally avoided for apomorphine hydrochloride solutions because the catechol ring degrades rapidly at high temperature; forced degradation studies show assay loss and green chromophore formation above 80 °C. Aseptic filtration through a 0.22 µm polyvinylidene fluoride or polyethersulfone membrane is used instead. Pre-filtration bioburden is controlled to ≤10 CFU/100 mL per USP <61>, and final sterility is confirmed per USP <71>. The bulk solution is prepared under nitrogen overlay in a stainless steel vessel, and amber Type I glass vials are flushed with sterile nitrogen to headspace oxygen below 2.0% v/v. The filling line operates at 60–200 vials per minute depending on needle diameter; in-process checks include fill volume, pH, and filter integrity by bubble point per ASTM F316-03. The solution is formulated in Water for Injection at 1.0–10.0 mg/mL apomorphine hydrochloride, with osmolality adjusted to 280–320 mOsm/kg using sodium chloride. The solution is protected from light during holding, filling, inspection, and storage. Published data for this specific apomorphine injectable configuration at lower veterinary dilution strengths is limited, so aseptic process simulation should include the actual antioxidant and headspace gas composition.

Extemporaneous oral solutions are prepared in citric acid–sodium citrate buffer at pH 3.0–4.0; sodium metabisulfite at 0.1% w/v is used as antioxidant, and the solution is stored in amber glass at 2–8 °C. Typical concentrations are 0.1–1.0 mg/mL. The solution is assayed by stability-indicating HPLC after 24 hours and at the intended beyond-use date; published stability data beyond 14 days are limited. Oral syringes with low extractable silicone content are preferred because apomorphine is surface-adsorptive at low concentrations. For granules and premixes, a fluid-bed granulation step with an ethanolic binder solution produces free-flowing granules. Granule moisture is held below 3.0% w/w, and drying air temperature is limited to 50–60 °C to avoid discoloration. The granulation endpoint is controlled by outlet air temperature and product impeller power draw rather than by fixed time alone; a product temperature above 45 °C causes oxidation. For a 1:1000 w/w premix, blend uniformity is tested by HPLC assay of ten stratified samples; acceptance is RSD ≤5.0% and mean assay within 90.0–110.0% of label claim. The premix is packaged in foil-lined low-density polyethylene bags under nitrogen. Apomorphine hydrochloride is not combined with alkaline diluents such as sodium bicarbonate, because free-base generation occurs above pH 5.0, nor with oxidizing agents such as povidone-iodine, chlorhexidine, or peroxide-based disinfectants. These incompatibilities are critical in multi-component powders and granules where residual disinfectants from equipment cleaning can induce oxidative loss.

D2 Receptor Cross-Reactivity and Species-Limited Emetic Response

Apomorphine is structurally derived from morphine but lacks clinically relevant µ-opioid receptor agonism at veterinary emetic doses; its action is mediated by D2 receptor agonism in the area postrema and nucleus tractus solitarius. This mechanism differs from xylazine and dexmedetomidine, which produce emesis through α2-adrenergic pathways and also cause sedation, bradycardia, and hypotension. Hydrogen peroxide induces vomiting by local gastric irritation and is associated with gastritis and foaming; apomorphine produces a centrally mediated response that cannot be surgically decontaminated by gastric lavage alone. The emetic response is strongly species-dependent: dogs are highly responsive, cats show inconsistent responses and may exhibit CNS excitation, and published data for apomorphine-induced emesis in horses, ruminants, and other non-canine species is limited and not considered routine. In dogs, overdose can cause respiratory depression, miosis, and protracted vomiting; published veterinary toxicology reviews recommend against repeated dosing after an initial failed emesis because the CNS depressant effect may dominate. The API is therefore controlled separately from dopamine antagonists such as metoclopramide and from opioid antagonists used in emergency reversal, to avoid pharmacy cross-contamination.

Compendial Release Criteria Reduce Batch Rejection Across Multi-Dosage Form Supply

Release testing for the veterinary API includes identification, assay, related substances, water content, residue on ignition, residual solvents, elemental impurities, and, for injectable grade, bacterial endotoxins and particulate matter. The table summarizes typical release criteria aligned with USP and Ph. Eur. monographs.

Compared with the apomorphine free base, the hydrochloride hemihydrate model offers higher water solubility and lower hygroscopicity, but it remains light-, oxygen-, and heat-sensitive. Compared with ropinirole hydrochloride and pramipexole dihydrochloride, which are D2/D3 agonists used for chronic parkinsonian signs, apomorphine hydrochloride is used in veterinary medicine primarily for acute emetic induction and not as a sustained oral dopaminergic replacement because of extensive first-pass metabolism and a short elimination half-life. The veterinary API is supplied as a dry powder to allow extemporaneous compounding of tablets, capsules, oral powders, granules, premixes, and injectable solutions, rather than as a ready-to-use human injection concentrate. This distinction is operationally important because the absence of preloaded sodium metabisulfite and sodium chloride means that each formulation must establish its own antioxidant compatibility, pH control, and terminal sterilization or aseptic filtration strategy.